Biotechnology

Antengene Announces Research Collaboration with Celularity to Evaluate the Potential Therapeutic Synergy of Combining Antengene's Best-in-Class Bispecific Antibody with Celularity's Natural Killer Cell Platform

- This research collaboration marks Antengene's entry into the field of cellular medicines. SHANGHAI and HONG KONGJuly 19, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discover...

2022-07-19 18:00 1840

WuXi AppTec Plans to Build a New Site in Singapore, Better Serving Global Partners and Advancing Healthcare Innovation

SINGAPORE, July 19, 2022 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, today announced a plan to build a new R&D and manufacturing site inSingapore. The company intends to invest up to S$2 bi...

2022-07-19 17:59 3802

Guo Guangchang Visits Fosun's Member Companies in Hamburg, Germany and Meets Carola Veit, President of Hamburg Parliament

HONG KONG, July 19, 2022 /PRNewswire/ -- On 18 July 2022, Mr. Guo Guangchang, Chairman of Fosun International, and his delegation visited Yuyuan inHamburg, and German lifestyle fashion brandTom Tailor. He also met and had lunch with Ms. Carola Veit, President of the Hamburg Parliament. Mr. Marco W...

2022-07-19 15:55 3507

Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China The amubarvimab/romlusevimab combination is the first locally-discovered and approved SARS-CoV-2 target-specific treatment inChina, evaluated through a rand...

2022-07-19 12:34 2853

llumina Among First in the World to Receive Approval of Science-Based Net-Zero Target

The Science Based Targets initiative has validated Illumina's targets to reach Net-Zero greenhouse gas emissions by 2050 SINGAPORE, July 19, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today it is among the first g...

2022-07-19 12:16 1712

Significant Glycemic Control and Weight Loss: Innovent Announces Phase 2 Study of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Met Primary Endpoint

SAN FRANCISCO and SUZHOU, China, July 19, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and o...

2022-07-19 08:00 3258

I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022

GAITHERSBURG, Md. and SHANGHAI, July 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that an abstract reporting the latest clinical data fro...

2022-07-18 20:00 1570

OliPass Moves Forward to Second Stage of Phase 2a Trial for Pain Killer OLP-1002

SEOUL, South Korea, July 18, 2022 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to move forward to the second stage of the Phase 2a trial inAustralia in osteoarthritis (OA) patients for pain killer OLP-1002, an SCN9A...

2022-07-18 20:00 1405

Samsung Biologics to purchase land for its second Bio Campus

* Acquires additional land, sized 357,366㎡ valued at KRW 426 billion, for Bio Campus 2 * Plans to build Multi-Modal Plant, Open Innovation, and expanded manufacturing capacities INCHEON, South Korea, July 18, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contrac...

2022-07-18 19:00 1364

CStone Announces the NDA Approval of GAVRETO® (pralsetinib) for the Treatment of RET Fusion-Positive treatment-naïve (first-line) and pretreated Non-Small Cell Lung Cancer (NSCLC) in Hong Kong, China

* GAVRETO is the first highly selective rearranged during transfection (RET) inhibitor approved inHong Kong, China for the treatment of RET fusion-positive metastatic non-small cell lung cancer * GAVRETO is CStone's second therapy approved in Hong Kong, China * GAVRETO is CStone's ninth NDA ...

2022-07-15 08:02 3172

Lunit to be Listed on KOSDAQ next week

* Initial Public Offering of 1,215,800 shares of its common stock at KRW 30,000 * To be listed on the KOSDAQ market on July 21, 2022 SEOUL, South Korea, July 14, 2022 /PRNewswire/ -- Lunit, a global provider of AI-based cancer solutions, announced that it priced its initial public offering (I...

2022-07-14 21:00 1865

Merck Launches its Uptune Program in Asia for Collaborating with Startups

* Application period for the Merck Uptune program starts today * Topics vary from AI-enabled health and cell and gene therapy tools to innovative technologies and materials in semiconductor and smart manufacturing * Selected startups can receive funding of up to € 100,000 SHANGHAI, July 14, ...

2022-07-14 20:16 5783

Urgent support needed following the pandemic's effect on cancer screening services

Dry July call to arms will improve support for cancer patients SYDNEY, July 14, 2022 /PRNewswire/ -- Dry July Foundation is urging Australians to dig even deeper this Dry July to help people affected by cancer. So many Australians could not access vital lifesaving cancer screenings and treatment...

2022-07-14 17:19 2581

Nanoform and Pharmanovia to breathe new life into iconic medicines

HELSINKI, July 14, 2022 /PRNewswire/ -- Nanoform Finland Plc., an innovative nanoparticle medicine-enabling company, today announced that it has partnered with Pharmanovia, a fast-growing specialty pharma business with a portfolio of over 20 branded drugs in 140 markets. The new strategic partne...

2022-07-14 13:55 1520

GenScript ProBio and DAAN Bio Therapeutics, Sign a Strategic Cooperation MOU for the Discovery and Development of Novel Drugs

SEOUL, South Korea, July 14, 2022 /PRNewswire/ -- On the July 14, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and DAAN Bio Therapeutics (Byoung Chul Cho, Co-Founder & CEO), an innovative new drug developer such as antibody treatments and cell therapy drugs, announced that the...

2022-07-14 13:00 2088

U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over

* Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S. * Immunizations with the Novavax COVID-19 Vaccine, Adjuvanted as a primary series will begin upon product release and once a policy recommendation from the CDC is received GAITHERSBURG, Md., July 14, 2022 /P...

2022-07-14 06:06 2432

miR Scientific is proud to announce the commercial availability of the miR Sentinel™ Prostate Cancer Test

NEW YORK, July 14, 2022 /PRNewswire/ -- miR Scientific, LLC announces the miR Sentinel™ Prostate Cancer Test is now commercially available in the United States, Puerto Rico and select international markets.  miR Sentinel™ is a novel, urine-based, molecular test that analyzes small non-coding RNA ...

2022-07-14 00:20 2100

Glenmark Pharmaceuticals and SaNOtize Announce Peer Reviewed Publication of Its Phase 3 Clinical Trials on SaNOtize's Novel Nitric Oxide Nasal Spray for COVID-19 in Lancet Journal

MUMBAI, India and VANCOUVER, BC, July 13, 2022 /PRNewswire/ -- Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven, global pharmaceutical company and SaNOtize Research and Development Corp, today announced thatThe Lancet Regional Health Southeast Asia (TLRHSEA) – peer reviewed, high...

2022-07-13 20:06 2539

Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer

Strategic executive hire adds to Company's global leadership team and positions the Company for continued growth DURHAM, N.C.and BEIJING, July 13, 2022 /PRNewswire/ -- Brii Biosciences Limited  ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national...

2022-07-13 19:00 2211

Subang Jaya Medical Centre Applauded by Frost & Sullivan for Its Leadership Position in the Malaysian Hospital Industry

SJMC is well positioned to drive the private hospital space into its next growth phase, capturing market share and sustaining its leadership in the coming years. SAN ANTONIO, July 13, 2022 /PRNewswire/ -- Recently, Frost & Sullivan researched the Malaysian hospital industry and, based on its ana...

2022-07-13 12:12 1817
1 ... 117118119120121122123 ... 275

Week's Top Stories